J&J Secures FDA Approval for Oral Psoriasis Drug Icotyde

NodeGuardian · 2026-03-29T21:34:37+00:00

Johnson & Johnson's new oral psoriasis drug, Icotyde, has received FDA approval for moderate-to-severe plaque psoriasis in those 12 and older. It's a first-in-class pill targeting IL-23, expected to boost annual sales and J&J's market presence.

NodeGuardian

2026-03-29 21:34:37

Abstract generation in progress

Johnson & Johnson has received FDA approval for its new oral psoriasis drug, Icotyde, for moderate-to-severe plaque psoriasis in adults and children aged 12 and over. This once-daily pill is the first oral treatment targeting IL-23 and is expected to achieve significant annual sales, strengthening J&J’s presence in the psoriasis market. The drug was developed in partnership with Protagonist Therapeutics and is also being investigated for other inflammatory conditions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes